Latest News

Each news article below shows only part of the news story. To view the full story, click on Read More below the story. 

  • December 12, 2018 2:55 PM | Anonymous

    December 12, 2018, Medgadget  

    Ob/Gyn Hologic is releasing in the U.S. its new Omni three-in-one hysteroscope, a device that gives physicians an option of three different sheaths on the same system. Using the Omni, one is not required to switch between diagnostic and operatives scopes, as it can serve different functions thanks to the three available sheaths. The product won U.S. Food and Drug Administration clearance earlier this month. 

    Read more.

  • December 11, 2018 2:03 PM | Anonymous

    December 11, 2018, HealthDay News via Monthly Prescribing Reference  

    From 2012 to 2016, there was a 61% increase in syphilis cases among pregnant women, with no traditional behavioral risk factors reported among half of these women, according to a study published online in Obstetrics & Gynecology. Researchers analyzed US national case report data from 2012 to 2016 to calculate trends among pregnant women with syphilis. They also examined the number of pregnant women in this population reporting high-risk behaviors. 

    Read more.

  • December 11, 2018 2:02 PM | Anonymous

    December 11, 2018, Health Central  

    Mayo Clinic researchers have found that the urinary incontinence medication oxybutynin (Oxytrol, Ditropan XL) can reduce the severity and frequency of hot flashes in menopausal women who aren't able to take hormone replacement therapy (HRT), including women who've had breast cancer. The researchers presented their findings at the 2018 San Antonio Breast Cancer Symposium.  

    Read more.

  • December 11, 2018 9:08 AM | Anonymous

    ARHP is supporting an important effort by the Planned Parenthood Federation of America (PPFA). Courtney Benedict, MSN, CNM, FNP of PPFA is conducting a survey of advanced practice clinicians (APCs), including nurse practitioners, nurse-midwives, licensed midwives and physician assistants, to assess their interest and engagement in working in the delivery of sexual and reproductive health (SRH) care. Specifically, this survey will:

    • Ask about your interest in and motivations for working in SRH
    • Identify needs of APCs interested in SRH work and
    • Identify needs of APCs already engaged in SRH

    This survey is part of a larger organizational project seeking to define motivators and barriers to APC’s participation in the SRH workforce. The findings from this study will be analyzed and published as potential strategies for the recruitment and retention of APCs in the SRH workforce.

    Your participation in this survey is voluntary and you can stop participation at any time. Your answers are anonymous and the data will be kept confidential and only shared publicly in aggregated forms which would prevent identification of individual responses.

    This survey should take approximately 15-20 minutes to complete and for your participation, you will have the option to be entered into a raffle to win one of several $250 gift cards. Your valuable time and insight is appreciated.

    If you have any questions, please contact Courtney Benedict at or at 415-828-1487.

    Click Here to Take the Survey

  • December 11, 2018 8:31 AM | Anonymous

    December 11, 2018, MedPage Today  

    Results of the 30-year prospective University of Kentucky Ovarian Cancer Screening Trial are adding to a body of evidence suggesting that an annual transvaginal ultrasound can detect early-stage ovarian cancer and improve survival rates for this patient population.

    Read more.

  • December 11, 2018 8:27 AM | Anonymous

    December 11, 2018, MedPage Today  

    Women's risk of breast cancer was highest about 5 years after childbirth, and lasted more than 20 years, compared with women who have never given birth, and breastfeeding did not appear to attenuate the risk, a large pooled analysis found. 

    Read more.

  • December 07, 2018 8:32 AM | Anonymous
    December 7, 2018, MedPage Today  

    Obesity may diminish survival in women with CLL who undergo chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR), a study from Germany found. 

    Read more.

  • December 06, 2018 8:24 AM | Anonymous
    December 6, 2018, Monthly Prescribing Reference b 

    Menopausal hormone therapy appears to reduce the risk of carpal tunnel syndrome in postmenopausal women, according to a study published in Plos One. To investigate the association between hormone therapy and carpal tunnel syndrome risk, researchers conducted a secondary analysis of the Women's Health Initiative (WHI) hormone therapy trials.  

    Read more.

  • December 06, 2018 8:21 AM | Anonymous
    December 6, 2018, HemOnc Today 

    Adjuvant ado-trastuzumab emtansine reduced risk for invasive recurrence by 50 percent compared with trastuzumab among patients with HER2-positive early breast cancer who still had residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy, according to results of the KATHERINE trial presented at San Antonio Breast Cancer Symposium. 

    Read more.

  • December 05, 2018 10:54 AM | Anonymous

    APAOG Annual Meeting Sponsorship Opportunities

    Consider sponsoring the APAOG Reception at the 2019 AAPA Annual Conference in Denver, CO!

    Event Details:

    Sunday, May 19th
    Time : TBD (evening) 
    Location: TBD 
    Denver, CO

    Sponsorship Details:

    • $5,000 Exclusive Sponsor 
    • $2,500 Partner Sponsor
    • $1,000 Affiliate Sponsor

    Exclusive Sponsor - 1 at $5,000 

    Includes Partner and Affiliate benefits listed below, as well as dedicated time to present at the event.

    Partner Sponsor - 1 at  $2,500

    Includes all Affiliate benefits below and:

    • Recognition on the website and all event promotion
    • Opportunity to place materials at APAOG Exhibit Booth at AAPA.
    • One quarter of advertising on APAOG website

    Affiliate Sponsor - 1 at $1,000

    Affiliate Sponsor Package Includes:

    • 2019 Affiliate APAOG Membership
    • Recognition on Welcome Signs at Event
    • Logo included on Email invitation to attendees. 

    Learn more here.

Powered by Wild Apricot Membership Software